• Explore /
  • Poster
  • / A phase III study (COSMIC-313) of cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in patients (pts) with previously untreated advanced renal cell carcinoma (aRCC) of intermediate or poor risk.

A phase III study (COSMIC-313) of cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in patients (pts) with previously untreated advanced renal cell carcinoma (aRCC) of intermediate or poor risk.

Abstract Poster

Authors

Toni Choueiri

Toni K. Choueiri

Dana-Farber Cancer Institute/Brigham and Women’s Hospital and Harvard University School of Medicine, Boston, MA

Toni K. Choueiri , Laurence Albiges , Thomas Powles , Christian Scheffold , Fong Wang , Robert J. Motzer

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 Genitourinary Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session C: Renal Cell Cancer

Track

Renal Cell Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT03937219

Citation

J Clin Oncol 38, 2020 (suppl 6; abstr TPS767)

Abstract #

TPS767

Poster Bd #

L1

Abstract Disclosures

Similar Posters

First Author: Toni K. Choueiri

First Author: J. Randolph Hecht

First Author: Pavlos Msaouel

First Author: Sumanta K. Pal